1 / 42

Opportunistic Infections in the Era of HAART: Are they gone?

South Dakota ACP Annual Meeting September 13, 2012. Opportunistic Infections in the Era of HAART: Are they gone?. Jennifer L. Hsu, MD Sanford Clinic Infectious Disease Assistant Professor, Sanford School of Medicine of The University of South Dakota. Financial Disclosures: None

tracen
Télécharger la présentation

Opportunistic Infections in the Era of HAART: Are they gone?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. South Dakota ACP Annual Meeting September 13, 2012 Opportunistic Infections in the Era of HAART: Are they gone? Jennifer L. Hsu, MD Sanford Clinic Infectious Disease Assistant Professor, Sanford School of Medicine of The University of South Dakota Financial Disclosures: None Unlabeled/Unapproved Uses Disclosure: None

  2. Learning Objective • Identify and outline appropriate diagnostic and therapeutic strategies for the most commonly seen HIV-associated infections in the era of highly active antiretroviral therapy.

  3. Incidence of Hospitalization, HIV Outpatient Study, 1994 – 2005 BuchaczK, et al. AIDS 2008;22:1345-56.

  4. Rates of Hospitalization, HIV Outpatient Study, 1994 – 2005 31% 7% 14% 9% BuchaczK, et al. AIDS 2008;22:1345-56.

  5. Incidence of AIDS-Defining OIs, HIV Outpatient Study, 1994 – 2007 High-Frequency Opportunistic Infections BuchaczK, et al. AIDS 2010;24:1549-59.

  6. Rates of OIs: HOPS and NHDS, 1996-2007 Kamimoto, et al. National HIV Prevention Conference 2011, Atlanta, GA, Poster 085M.

  7. OIs and Mortality CASCADE Collaboration. AIDS 2006;20:741-749.

  8. Where do OIs occur in the U.S. now? • Unaware of HIV positivity • Presentation toemergency care with late-stage manifestations of AIDS • Aware of HIV positivity • Remain unlinked to care • Psychosocial or economic factors  unable to take HAART • Poor adherence  poor virologic suppression or immune reconstitution • Extensive antiretroviral resistance • Lack of appropriate infection prophylaxis Brooks J, et al. Clin Infect Dis 2009;48:609-11.

  9. Case 1 • 53 yo male diagnosed with HIV through routine screening – CD4 8 cells/μland HIV RNA 88,000 copies/ml • Presents with persistent fever, fatigue, and weight loss, as well as intermittent diarrhea • BP 116/56|Pulse 84|Temp 38.1 °C|SpO2 97% • Exam notable for cachexia, diffuse abdtendernesswith hepatosplenomegaly

  10. Case 1 (cont.) • Abnormal labs: • Hct 24% • Alkaline phosphatase 360 • CT: hepatosplenomegaly with multiple enlarged nodes

  11. Which of the following the most appropriate next step? • Initiate ART and prophylaxis with TMP-sulfa and azithromycin. • Lymph node biopsy. • Bone marrow biopsy. • Blood culture for acid-fast organisms. • Initiate 4-drug therapy for tuberculosis.

  12. MAC Basics • Most common bacterial OI in developed world • Affects 10-20% of persons living with AIDS • Independent predictor of mortality even when adjusted for CD4 count Incidence of MAC infection in patients with a CD4 count <200/L, Johns Hopkins HIV clinic cohort, 1991–2003 Moore RDand Chaisson RE. Ann Intern Med 1996;124:633–42. KarasouksisP, et al. Lancet Infect Dis 2004;4:557-65.

  13. Survival with MAC, Johns Hopkins HIV Clinic Cohort, Pre- vs. Post-HAART Moore RDand Chaisson RE. Ann Intern Med 1996;124:633–42.

  14. Non-Specific Presentation of MAC Gordin FM, et al. J Infect Dis 1997;176:126-32.

  15. Features Favoring MAC Over TB • Hepatosplenomegaly • Elevated alkaline phosphatase (> 2x ULN) • Elevated GGT (> 3x ULN) • Leukopenia • CAVEAT: Distinguishing between the 2 diagnoses may be complicated by epidemiologic factors Rolla V, et al. Rev Inst Med Trop Sao Paulo 1999;41:273–77.

  16. Diagnosis of Disseminated MAC • Recovery from a normally sterile body site • Mycobacterial blood cultures • >90% yield with 2 blood cultures • Growth typically occurs by day 14  DNA probe • Bone marrow biopsy rarely necessary • Positive culture from a stool or respiratory specimen indicates increased risk of disseminated disease, but is not diagnostic Spach D and Gallant J. HIV Web Study, University of Washington, 10/14/07. Accessed 8/31/12.

  17. Treatment Regimens • Macrolides achieve high intra-macrophage levels where MAC organisms are concentrated and ethambutol protects against development of resistance • Secondary prophylaxis may be discontinued CD4 >100 cells/mm3 for 6 months and they have completed 12 months of MAC therapy without ongoing clinical evidence of infection Kaplan J, et al. MMWR 2009;58(4):1-217.

  18. Case 2 • 30 yo male with no known medical history presented to the ED for dry cough and SOB • 2 ED visits for URI symptoms and coughin the preceding week • Recently relocated from AZ to MN • BP 116/56 | Pulse 106 | Temp36.8 °C | Resp24 | SpO2 93% • Appearsacutelydistressed

  19. What is the diagnostic test of choice? • Serum cryptococcal antigen • Sputum for AFB smear and culture • (1→3)-ß-D-glucanassay (Fungitell®) • Serum galactomannan (Aspergillus antigen) • Sputum for GMS staining • Serum coccidoidesantibodies

  20. It’s a Fungus! Cyst forms in GMS-stained BAL fluid Wright-Giemsa–stained trophic forms Calcofluor-stained fungal cell walls DFA of cysts

  21. Diagnostic Testing • Direct visualization required since organism cannot be cultured • Quick, widely available, but requires pathologist • GMS, Wright-Giemsa, calcofluor white • Induced sputum, tracheal aspirate, or BAL • Microscopy 50-90% sensitive in HIV patients • PCR  very sensitive; ?detect colonization Thomas and Limper. N Eng J Med 2004;350(24):2487-98.

  22. Clinical Pearls: HIV vs. Non-HIV Thomas and Limper. N Eng J Med 2004;350(24):2487-98.

  23. Treatment Options Thomas and Limper. Nat Rev Microbiol2007;5(4):298-308.

  24. Case 3 • 43 yo HIV-infected woman with a CD4 count of 22 cells/μlpresents with decreased vision in her left eye with new floaters. • She was diagnosed with HIV 1 year prior, but has not been engaged in care. She takes TMP-sulfa, but no other medications. • On examination, she has decreased visual acuity in her left eye. She is urgently referred to an ophthalmologist for evaluation of suspected cytomegalovirus (CMV) retinitis. Spach D and Chuang E. HIV Web Study, University of Washington, 10/14/07. Accessed 8/31/12.

  25. Which of the following is true? • CMV retinitis in HIV-infected patients usually results from reactivation disease due to previous infection. • In this situation, ART would be sufficient for treatment. • This patient had unusual presenting manifestations of CMV retinitis. Most patients present with eye pain, erythema, and vision loss. • The diagnosis of the CMV retinitis should be confirmed by use of PCR on vitreous fluid.

  26. CMV Basics • Retinitis is most common CMV manifestation • Major risk is CD4 count <50 cells/μl, but HIV RNA >100,000 copies/ml and concomitant MAC also risk • Reactivation of latent infection Spach D and Gallant J. HIV Web Study, University of Washington, 10/14/07. Accessed 8/31/12.

  27. 4 “F’s” of CMV Retinitis • Floaters • Flashes • Field deficits • Failing vision • Typically unilateral • No associated pain or redness • Diagnosed with dilated eye exam • Typically, no role for lab testing (serum or vitreous fluid)

  28. Intra-Ocular vs. Systemic Therapy Musch DC, et al. N Engl J Med1997;337:83-90. Martin DF, et al.N Engl J Med2002;346:1119-26. Spach D and Gallant J. HIV Web Study, University of Washington, 10/14/07. Accessed 8/31/12.

  29. Findings From CMV Retinitis Trials • Implant is more effective than intravenous ganciclovir for treating the affected eye • Implant alone is ineffective for prevention of contralateral involvement or extraocular disease • Implant plus oral ganciclovir is more effective than the implant alone for prevention of new CMV disease • Oral valganciclovir alone is at least as effective as IV ganciclovir Musch DC, et al. N Engl J Med1997;337:83-90. Martin DF, et al.N Engl J Med2002;346:1119-26. Spach D and Gallant J. HIV Web Study, University of Washington, 10/14/07. Accessed 8/31/12.

  30. Case 4 • 31 yo male immigrant from Guatemala presents with fever and new-onset seizure • Diagnosed with HIV/AIDS 3 months prior during hospitalization for Salmonella bacteremia • Has not taken any medications since discharge • BP 140/78| Pulse 90 | Temp37.8 °C | Resp18 | SpO2 99% • Exam notable for decreasedlevel of alertness and right-sidedweakness Spach D and Gallant J. HIV Web Study, University of Washington, 10/14/07. Accessed 8/31/12.

  31. Case 4 (cont.) • Blood cultures again grow Salmonella • Toxoplasma IgM negative; IgG positive • CT head with contrast shows multiple ring-enhancing lesions with surrounding vasogenic edema

  32. Which of the following is true? • The presence of >1 mass lesion rules out CNS lymphoma. • Approximately 10% of primary CNS lymphomas in patients with AIDS are EBV-associated. Performing CSF PCR does not provide additional information. • Based on the findings, primary CNS lymphoma is most likely and radiation therapy should be started. • Based on the findings, Toxoplasma encephalitis is most likely and therapy with pyrimethamine, sulfadiazine, and leucovorin should be started.

  33. Toxoplasma Basics • Protozoan parasite that infects humans as incidental hosts • Cats are definitive host (40% domestic cats, 60% stray cats seropositive for T. gondii) • Fecal-oral transmission or ingestion of undercooked meat • Primary infection: asymptomatic or mononucleosis-like

  34. Incidence of Toxoplasma Encephalitis, HIV Outpatient Study, 1994 – 2007 Buchacz K, et al. AIDS 2010;24:1549-59.

  35. Reactivation in HIV • Reactivation of latent organisms  symptomatic disease • 85% of HIV-infected persons with toxo have CD4 <100 cells/μl • Most common presentation is focal encephalitis – seizures, focal neurologic deficits • Uncommon presentations (1-2%): • Retinitis • Pneumonitis • Disseminated disease • Lifetime risk of developing toxo encephalitis in seropositive AIDS patient not on prophylaxis is 10-50% Richards FO Jr, et al. ClinInfect Dis1995;21 Suppl 1:S49-56.

  36. Clinical Approach Toxoplasma encephalitis Primary CNS lymphoma Negative toxo serology Appropriate use of prophylaxis Solitary brain lesion on MRI Positive CSF PCR for EBV • Positive IgG (~95% positive) • Non-use of prophylaxis • Multiple enhancing brain lesions in MRI • Positive CSF PCR for T. gondii • Empiric therapy recommended for multiple enhancing lesions • Brain biopsy reserved for non-response to therapy

  37. Time to Neurologic Response • Best-studied: • Pyrimethamine • Sulfadiazine • Leucovorin • Clindamycin may be substituted for sulfa (risk of relapse increases) • Corticosteroids? Luft BJ, et al. N Engl J Med 1993;329:995-1000.

  38. Prevention is Key • Early diagnosis and initiation of HAART • Immunizations • Annual influenza • 23-valent pneumococcal (baseline and q5 years) • Td/Tdap (q10 years) • Hepatitis A and/or B (if seronegative) • HPV based on age • Consider VZV and/or MMR as appropriate in HIV-infected persons with CD4 count >200 cells/μL Kaplan J, et al. MMWR 2009;58(4):1-217.

  39. Chemoprophylaxis Kaplan J, et al. MMWR 2009;58(4):1-217.

  40. Challenges in the U.S. • OI are still common • Late detection in some regions, urban and rural • Occurrence pre- and post-HAART • Considerable mortality attributable to OIs • Expertise in management may be waning • Early initiation of HAART is the best prevention

  41. Useful Resources • www.aidsinfo.nih.gov • HIV Treatment Guidelines for Adults and Adolescents • Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents • http://depts.washington.edu/hivaids/index.html • Web-based HIV case study

More Related